G1 Therapeutics (GTHX) Set to Announce Earnings on Wednesday
G1 Therapeutics (NASDAQ:GTHX) will announce its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.
Shares of G1 Therapeutics (NASDAQ GTHX) opened at $19.69 on Tuesday. G1 Therapeutics has a twelve month low of $12.04 and a twelve month high of $28.67. The firm has a market capitalization of $558.12 and a price-to-earnings ratio of -9.16.
In other G1 Therapeutics news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $19.75, for a total value of $3,950,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Rajesh Malik sold 3,776 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $20.00, for a total value of $75,520.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 350,458 shares of company stock worth $6,939,148.
Several analysts recently weighed in on GTHX shares. Cowen restated a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. BidaskClub upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. increased their price target on G1 Therapeutics to $30.00 in a report on Monday, February 5th. Finally, BTIG Research started coverage on G1 Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $32.80.
About G1 Therapeutics
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.